Methods of treating impaired wound healing
AssigneeZafgen, Inc.
InventorsThomas E. Hughes, James E. Vath
Life of this patent
Estimating the term…
Abstract
The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.
Claims15
A method of treating a patient suffering from impaired wound healing, and in need thereof, comprising administering to the patient an effective amount of a MetAP2 inhibitor, wherein the MetAP2 inhibitor is selected from the group consisting of 6-O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable salts thereof.
A method for treating impaired wound healing in a patient in need thereof, comprising administering to the patient an effective amount of a MetAP2 inhibitor, wherein said effective amount does not substantially modulate or suppress angiogenesis.
A method for treating impaired wound healing in a patient in need thereof, comprising administering to the patient an effective amount of a MetAP2 inhibitor.
Dependencies are inferred from the claim text.